Further studies of how CAFs affect the p53 response to DNA-damaging chemotherapeutic drugs in tumor cells may provide novel opportunities for efficient cancer therapy aimed at blocking pro-survival signaling from the tumor microenvironment. The gene discussed is TP53; the disease is cancer.